Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Has announcements × mCRPC × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 55 Breast Neoplasms 32 Neoplasms 29 Parkinson Disease 4, Autosomal Dominant Lewy Body 23 Multiple Myeloma 21 Recurrence 18 Leukemia, Myeloid, Acute 16 Colorectal Neoplasms 16 Neoplasm Metastasis 15 Lymphoma, Non-Hodgkin 15 Melanoma 14 Leukemia, Lymphocytic, Chronic, B-Cell 13 Leukemia 13 Lymphoma, Follicular 12 Carcinoma, Renal Cell 12 Precursor Cell Lymphoblastic Leukemia-Lymphoma 11 Ovarian Neoplasms 11 Myelodysplastic Syndromes 10 Lymphoma, Large B-Cell, Diffuse 10 Lung Neoplasms 10 Urinary Bladder Neoplasms 9 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9 Hematologic Neoplasms 9 Carcinoma, Hepatocellular 9 Adenocarcinoma 9 Small Cell Lung Carcinoma 8 Prostatic Neoplasms 8 Lymphoma, Mantle-Cell 8 Lymphoma, B-Cell, Marginal Zone 8 Head and Neck Neoplasms 8

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡